Leukemic stem cells modulate the bone marrow microenvironment
ESH eLearning, Bonnet Dominique, 219256
Is transplant needed to cure Ph+ ALL in patients who achieve MRD negativity? - No
ESH eLearning, Farhad Ravandi-Kashani, 219257
An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias
ESH eLearning, Arnold Ganser, 226249
The devastating effects of relapsed or refractory AML
ESH eLearning, Arnold Ganser, 226250
From bench to the bedside: understanding the genetic changes in AML
ESH eLearning, Arnold Ganser, 226251
Finding the right targets for CAR T-cell therapy in AML
ESH eLearning, Arnold Ganser, 226252
Midostaurin: the first drug to receive approval for AML since 2000
ESH eLearning, Arnold Ganser, 226253
Overcoming the issues with clinical trial recruitment
ESH eLearning, Arnold Ganser, 226254
Transplantation clinical trial network to build available prospective studies on AML
ESH eLearning, Charles Craddock, 226255
Current understandings of ALL approaches
ESH eLearning, Charles Craddock, 226256
Challenges with the identification of ALL subtypes
ESH eLearning, Charles Craddock, 226257
Immunotherapies for the treatment of AML
ESH eLearning, Christoph Röllig, 226264
Managing AML in elderly patients
ESH eLearning, Christoph Röllig, 226265
Biological rationales when determining AML therapies
ESH eLearning, Christoph Röllig, 226266
Targeting IDH mutations for the treatment of AML
ESH eLearning, Eytan Stein, 226267
Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?
ESH eLearning, Eytan Stein, 226268
Primary and secondary resistance in AML
ESH eLearning, Eytan Stein, 226269
Encouraging patients to participate in AML trials
ESH eLearning, Eytan Stein, 226270
The latest clinical trials into novel AML therapies
ESH eLearning, Eytan Stein, 226271
The complications of treating elderly patients with AML
ESH eLearning, Gail Roboz, 226272
Managing relapse in AML: the role of MRD
ESH eLearning, Gail Roboz, 226273
Involving the patient is a key part of cancer treatment
ESH eLearning, Mark Levis, 226280
CAR T-cell therapy and ALL: the current landscape
ESH eLearning, Noelle Frey, 226281
The CAR T-cell therapy race
ESH eLearning, Noelle Frey, 226282
The importance of MRD assessment in all phases of ALL treatment
ESH eLearning, Noelle Frey, 226283
Next-generation methodologies: the future for MRD monitoring in ALL?
ESH eLearning, Wendy Stock, 226284
Emerging novel approaches for ALL: inotuzumab ozogamicin
ESH eLearning, Wendy Stock, 226285
Support systems are a crucial factor in ALL treatment
ESH eLearning, Wendy Stock, 226286
Bone marrow transplant in red cell disorders
ESH eLearning, eliane Gluckman, 219043
Sickle cell disease pathophysiology
ESH eLearning, Jacques Elion, 219038
ESH eLearning, Maria Domenica Cappellini, 219039
Malaria and red cell disorders
ESH eLearning, Michael Lanzer, 219040
Epidemiology of red cell disorders
ESH eLearning, Frédéric B. Piel, 219041
Red cell senescence and storage lesions
ESH eLearning, Giel Bosman, 219042
Erythroid niche and erythroblast maturation
ESH eLearning, Mohandas Narla, 219034
Epigenetics in erythropoiesis
ESH eLearning, Gordon D. Ginder, 219035
Heme synthesis and iron metabolism
ESH eLearning, Laurent Gouya, 219036
Red cells and oxidative stress
ESH eLearning, Lucia De Franceschi, 219037
Richter transformation in the elderly patient:molecular origin and new strategies for improved therapies
ESH eLearning, Davide Rossi, 212197
Targeting the DNA Damage Response in high-risk lymphoma: biology and insights for future, less toxic approaches of therapy
ESH eLearning, Christian REINHARDT, 212198
Double hit and other types of high-risk lymphoma:molecular features and optimal management in the elderly patient
ESH eLearning, Paul Hamlin, 212199
Biology of AML at older age
ESH eLearning, Terrence N. Wong, 212185
Therapeutic management of the so-called “fit” older patient with AML
ESH eLearning, Bob Löwenberg, 212186
Management of the unfit patient with AML
ESH eLearning, Gert Ossenkoppele, 212187
The older patient with ALL
ESH eLearning, Hervé Dombret, 212188
Alloegeneic stem cell transplantation at older age
ESH eLearning, Nicolaus Kröger, 212189
Clonal evolution of multiple myeloma
ESH eLearning, Nikhil Munshi, 212190
MGUS and MGUS transition to myeloma, what do we need to do?
ESH eLearning, Irene Ghobrial, 212191
Multiple myeloma in the elderly, a particular challenge in light of numerous novel agents.
ESH eLearning, Jesús F. San-Miguel, 212192
Clonal evolution in malignant lymphoma
ESH eLearning, Jude FITZGIBBON, 212193
Management of indolent lymphoma in the elderly patient
ESH eLearning, Loretta Nastoupil, 212194
Management of comorbidity and specific adverse events in the era of novel kinase inhibitors (ibrutinib, idelalisib, venetoclax) for lymphoid malignancies
ESH eLearning, Farrukh Awan, 212195
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma
ESH eLearning, Loretta Nastoupil, 212196
DNA damage, a driving force of aging
ESH eLearning, Björn Schumacher, 212174
Clonal hematopoiesis
ESH eLearning, Benjamin Ebert, 212175
Clonal hematopoiesis
ESH eLearning, George Vassiliou, 212176
Selection of TP53 mutant clones following chemotherapy
ESH eLearning, Terrence N. Wong, 212177
Aging stem cells and stress
ESH eLearning, Michael Milsom, 212178
Anemia at older age
ESH eLearning, Nancy Berliner, 212179
Microenvironment and MDS
ESH eLearning, Rebekka Schneider, 212180
Biology of MDS
ESH eLearning, Benjamin Ebert, 212181
Management of high grade MDS
ESH eLearning, Pierre Fenaux, 212182
Management of CMML and other MDS/MPN entities
ESH eLearning, Raphael Itzykson, 212183
Assessing the aging individual with hematologic disorders: How geriatric assessment can define the fitness of an older patient
ESH eLearning, Tanya Wildes, 212184
The pathology of marginal zone lymphomas
ESH eLearning, German Ott, 210034
Marginal zone lymphoma: biology and molecular genetics
ESH eLearning, Ming Qing Du, 210035
Marginal zone lymphoma. Prognostic models.
ESH eLearning, Carlos Montalban, 210036
Clinical aspects
ESH eLearning, Catherine Thieblemont, 210037
Treatment of splenic marginal zone lymphoma
ESH eLearning, Barbara Kiesewetter, 210038
Treatment of nodal marginal zone lymphoma
ESH eLearning, Catherine Thieblemont, 210039
Treatment of MALT lymphoma
ESH eLearning, Emanuele Zucca, 210040
Novel targeted therapies in CL - Ibrutinib
ESH eLearning, John Gribben, 210025
ESH eLearning, Michael J. Keating, 210026
ESH eLearning, Peter Hillmen, 210027
Follicular lymphoma; from genetics to pathogenesis
ESH eLearning, Riccardo Dalla-Favera, 210028
Clonal evolution of follicular lymphoma
ESH eLearning, Michael R. Green, 210029
Integrating molecular diagnostics for improved patient stratification in follicular lymphoma
ESH eLearning, Oliver Weigert, 210030
Advanced stage patient, first line
ESH eLearning, Christian BUSKE, 210031
Treatment of follicular lymphoma (FL): Salvage therapy
ESH eLearning, Vincent Ribrag, 210032
New agents
ESH eLearning, Gilles Salles, 210033
Micro RNA dysregulation to identify targets for therapy in hematopoietic malignancies
ESH eLearning, Carlo M. Croce, 210019
Genetic portrait of CLL
ESH eLearning, Cathy Wu, 210020
Predictive biomarkers in CLL
ESH eLearning, Davide Rossi, 210021
ESH eLearning, Michael J. Keating, 210022
ESH eLearning, Olivier Tournilhac, 210023
Chlorambucil plus anti-CD20 MoAb
ESH eLearning, Valentin Goede, 210024
Myeloma Hub
ESH eLearning, ESH , 204612
iCMLf Prize talk
ESH eLearning, Jerry Radich, 205141
John Goldman Prize Talk
ESH eLearning, Tim Hughes, 205140
Janet Rowley Prize talk
ESH eLearning, Mhairi Copland, 205142
The need for collaboration amongst hospitals: learning from RATIFY
ESH eLearning, Miguel Sanz, 204652
Why are new molecules typically combined with standard chemotherapy?
ESH eLearning, Miguel Sanz, 204653
Integrating midostaurin into FLT3 positive AML treatment
ESH eLearning, Miguel Sanz, 204654
The challenges of using kinase inhibitors for AML treatment
ESH eLearning, Mark Levis, 204668
Venetoclax for elderly AML patients
ESH eLearning, Mark Levis, 204669
The drugs being used to treat newly diagnosed AML patients
ESH eLearning, Mark Levis, 204670
Mimetics: the future of AML treatment?
ESH eLearning, Andrew Wei, 204684
Highly targeted medication for AML
ESH eLearning, Andrew Wei, 204685
Translational research in Berlin to improve AML treatment outcomes
ESH eLearning, Lars Bullinger, 204700
Reassuring patients with AML
ESH eLearning, Lars Bullinger, 204701

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings